Mission
Bio-Converts mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-02, uses a novel drug delivery technology, that enables more precise, effective and efficient treatment.
Vision
Bio-Converts visions is to revolutionize the treatment of oral leukoplakia, with our unique QR-02 gel. Aimed at minimizing or remove oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.
Background
Oral leukoplakia is a potentially cancerous white patch or plaque in the mouth, strongly linked to smoking. The edges of the lesion are typically abrupt and the lesion changes.
Oral leukoplakia also has dysplasia which highlights the severity of the disorder and is a marker of disease progression.
Dysplasia is abnormal cell growth, a precancerous condition more serious than normal cell overgrowth (hyperplasia).
In adults, precancerous dysplasia may not always turn into cancer, but there’s a risk it could.
Bio-Convert have identified a novel drug delivery technology, that we believe holds significant potential to become the preferred future treatment of oral leukoplakia (OL) using our unique gel, QR-02.
The gel is applied directly
to the lesions in the mouth.
The treatment is intended to reduce/remove the OL lesions, and it will facilitate surgical procedure and improve, and reduce the malign conversion rate, lowering the risk of them turning into cancer.
Management
Allan Wehnert
CEO & Founder
Allan Wehnert has over 30 years in the pharmaceutical industry, specializing in discovering and developing new molecules for central nervous system disease treatment. A trained pharmacologist, he’s authored 25 scientific papers in prestigious international journals. Previously during his former employment, as Initiator Pharma’s Senior VP for Research and Development, he advises private equity syndicates and owns Decision Insights.
During his 25-year tenure as Senior VP at Lundbeck, Allan led drug development from pre-clinical stages to NDA/EMA approval. He played a key role in bringing 6 products to market and overseeing over 75 due diligence processes, along with more than 7 asset and company acquisitions.
Board of Directors
Peter Severin
Chairman
Peter Severin brings over 25 years life sciences and sales experience to Orocidins Board. Mr. Severin is currently the Founder and CEO of Severin Partners, a sales and communications consulting company focusing on the healthcare industries.
He also serves as Chairman of the U.S.-based Life Sciences holding company, Nordicus Partners Corporation. Prior to founding Severin Partners, Peter held positions as Head of Sales of Novartis AG, Sales Manager at AstraZeneca Pharmaceuticals and as Sales Manager of GSK Plc (formerly GlaxoSmithKline Plc).
Henrik Rouf
Member
Henrik Rouf has 30 years of experience in the global finance markets, working as an international financier, merchant banker and fund manager, respectively. Mr. Rouf advises and finances companies in many industries, including (though not limited to)
software, semiconductors, blockchain, healthcare, medical devices, biotechnology, restaurant chains, apparel, cannabis, clean tech and advertising.
Mr. Rouf has since 2004 been the President of PacificWave Partners Inc., a California-based merchant bank, and is also currently the CEO of the U.S. based Life Sciences holding company, Nordicus Partners Corporation. By being located and working in the United States for more than 30 years, Mr. Rouf has a vast network and extensive ties to especially the U.S., but also to Europe and Asia.
Christian Hill-Madsen
Member
Christian Hill-Madsen has over 25 years of experience in the Life Sciences industry, including serving as a headhunter.
He possesses an extensive network and unique knowledge within the Life
Sciences/Biotech sector, and has proven experience in identifying top talent, build strong teams, and improve organizational structures. This expertise in talent acquisition and workforce dynamics plays a key role in ensuring the companies he is involved with is well-positioned with the right people to support its growth and innovation.